NextCure approves 1-for-12 reverse stock split effective July 14, 2025

NextCure, Inc.

Board approved 1:12 reverse stock split; effective July 14, 2025 with split-adjusted trading at market open.
Every 12 shares convert into 1 share; fractional shares paid in cash based on prior day's closing price.
Outstanding equity awards, incentive plans, and exercise prices adjusted proportionally to the split.
No change to common stock par value; trading symbol remains NXTC on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.